In The Spotlight
- 12 September 2017 - 14 September 2017
- Malmömassan – Malmö Convention Center Mässgatan 6 215 32
- Malmö – Sweden
- 06 March 2017 - 08 March 2017
- The Intrepid Sea, Air and Space Museum
- The Times Center, New York
- 07 February 2017 - 09 February 2017
- PGA National Resort & Spa, Palm Beach Gardens, FL
- 05 May 2017 - 07 May 2017
- Bologna Fair Centre
- Bologna, Italy
- 07 November 2017 - 10 November 2017
- Shanghai New International Exhibition Centre (SNIEC)
- Shanghai ,China
Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody.
University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes.
H. Lundbeck A/S is collaborating with IBM's Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders.
DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new cancer therapies.
ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types announced that they are initiating enrolment of the first patient in the phase 1 clinical trial for varlitinib (ASLAN001) in biliary tract cancer in Japan.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma.
Aldevron, a leading biotechnology contract manufacturing and development organization, is now using a 30-liter single-use fermentation system for manufacturing nucleic acids and proteins.
Mundipharma and Helsinn Group have expanded their collaboration, signing amendments to licensing and distribution agreements for anti-emetic prophylactic agents ALOXI® and AKYNZEO® to cover a host of additional markets.
AMAG Pharmaceuticals, Inc. and Endoceutics, Inc. announced that they have entered into an exclusive license agreement that provides AMAG with U.S. commercial rights to Intrarosa™ (prasterone).
The latest in rigid and flexible packaging materials for medical device and pharmaceutical applications will be featured by Tekni-Films, a Tekni-Plex company, at MD&M West, February 7-9, Anaheim Convention Center, Anaheim, Calif., in Booth 2027.
Klöckner Pentaplast will present the latest range of pharmaceutical packaging solutions and services at Pharmapack 2017 (Booth A30), February 1-2, 2017, in Paris, France.
Yokogawa Electric Corporation announces that it has developed an ISA100 Wireless™ based field wireless vibration sensor with the ability to quickly update data and a long battery life, and will release it in markets other than Japan on December 7.
ICON plc a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US FDA to validate three PRO instruments that will measure clinical endpoints in antibacterial drug trials.
Takeda Pharmaceutical Company Limited announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc for $24.00 per share in cash.
Thermo Fisher Scientific Inc, the world leader in serving science completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction.
Regenerative and cell-based therapies have only recently begun to deliver on the promise they have portended for years, creating opportunities to positively impact patient outcomes and professional success.
Type 2 diabetes awareness is rising in the United States. Public and private health leaders are now offering screenings and patient education sites that discuss “prediabetes,” to detect and treat the disease in its earliest stages.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.
Clintec announces the launch of its new brand identity – reflected in their newly created website. This in part marks Clintec’s 20th anniversary and the achievement of significant milestones following another year of substantial growth, together with a succession of key appointments that have enhanced the global leadership team.
GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform.
Intarcia Therapeutics, Inc. announced that the U.S. FDA has accepted for active review its NDA for ITCA 650, an investigational therapy for the treatment of type 2 diabetes (T2D).